File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Tubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition

TitleTubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition
Authors
Issue Date1-Oct-2023
PublisherOxford University Press
Citation
Nephrology Dialysis Transplantation, 2023, v. 38, n. 10, p. 2232-2247 How to Cite?
Abstract

Background

Thromboembolic events are prevalent in chronic kidney disease (CKD) patients due to increased thrombin generation leading to a hypercoagulable state. We previously demonstrated that inhibition of protease-activated receptor-1 (PAR-1) by vorapaxar reduces kidney fibrosis.

Methods

We used an animal model of unilateral ischemia–reperfusion injury-induced CKD to explore the tubulovascular crosstalk mechanisms of PAR-1 in acute kidney injury (AKI)-to-CKD transition.

Results

During the early phase of AKI, PAR-1-deficient mice exhibited reduced kidney inflammation, vascular injury, and preserved endothelial integrity and capillary permeability. During the transition phase to CKD, PAR-1 deficiency preserved kidney function and diminished tubulointerstitial fibrosis via downregulated transforming growth factor-β/Smad signaling. Maladaptive repair in the microvasculature after AKI further exacerbated focal hypoxia with capillary rarefaction, which was rescued by stabilization of hypoxia-inducible factor and increased tubular vascular endothelial growth factor A in PAR-1-deficient mice. Chronic inflammation was also prevented with reduced kidney infiltration by both M1- and M2-polarized macrophages. In thrombin-induced human dermal microvascular endothelial cells (HDMECs), PAR-1 mediated vascular injury through activation of NF-κB and ERK MAPK pathways. Gene silencing of PAR-1 exerted microvascular protection via a tubulovascular crosstalk mechanism during hypoxia in HDMECs. Finally, pharmacologic blockade of PAR-1 with vorapaxar improved kidney morphology, promoted vascular regenerative capacity, and reduced inflammation and fibrosis depending on the time of initiation.

Conclusions

Our findings elucidate a detrimental role of PAR-1 in vascular dysfunction and profibrotic responses upon tissue injury during AKI-to-CKD transition and provide an attractive therapeutic strategy for post-injury repair in AKI.


Persistent Identifierhttp://hdl.handle.net/10722/338828
ISSN
2021 Impact Factor: 7.186
2020 SCImago Journal Rankings: 1.654

 

DC FieldValueLanguage
dc.contributor.authorLok, Sarah W Y-
dc.contributor.authorYiu, Wai Han-
dc.contributor.authorZou, Yixin-
dc.contributor.authorXue, Rui-
dc.contributor.authorLi, Hongyu-
dc.contributor.authorMa, Jingyuan-
dc.contributor.authorChen, Jiaoyi-
dc.contributor.authorChan, Loretta Y Y-
dc.contributor.authorLai, Kar Neng-
dc.contributor.authorTang, Sydney C W-
dc.date.accessioned2024-03-11T10:31:51Z-
dc.date.available2024-03-11T10:31:51Z-
dc.date.issued2023-10-01-
dc.identifier.citationNephrology Dialysis Transplantation, 2023, v. 38, n. 10, p. 2232-2247-
dc.identifier.issn0931-0509-
dc.identifier.urihttp://hdl.handle.net/10722/338828-
dc.description.abstract<p>Background</p><p>Thromboembolic events are prevalent in chronic kidney disease (CKD) patients due to increased thrombin generation leading to a hypercoagulable state. We previously demonstrated that inhibition of protease-activated receptor-1 (PAR-1) by vorapaxar reduces kidney fibrosis.</p><p>Methods</p><p>We used an animal model of unilateral ischemia–reperfusion injury-induced CKD to explore the tubulovascular crosstalk mechanisms of PAR-1 in acute kidney injury (AKI)-to-CKD transition.</p><p>Results</p><p>During the early phase of AKI, PAR-1-deficient mice exhibited reduced kidney inflammation, vascular injury, and preserved endothelial integrity and capillary permeability. During the transition phase to CKD, PAR-1 deficiency preserved kidney function and diminished tubulointerstitial fibrosis via downregulated transforming growth factor-β/Smad signaling. Maladaptive repair in the microvasculature after AKI further exacerbated focal hypoxia with capillary rarefaction, which was rescued by stabilization of hypoxia-inducible factor and increased tubular vascular endothelial growth factor A in PAR-1-deficient mice. Chronic inflammation was also prevented with reduced kidney infiltration by both M1- and M2-polarized macrophages. In thrombin-induced human dermal microvascular endothelial cells (HDMECs), PAR-1 mediated vascular injury through activation of NF-κB and ERK MAPK pathways. Gene silencing of PAR-1 exerted microvascular protection via a tubulovascular crosstalk mechanism during hypoxia in HDMECs. Finally, pharmacologic blockade of PAR-1 with vorapaxar improved kidney morphology, promoted vascular regenerative capacity, and reduced inflammation and fibrosis depending on the time of initiation.</p><p>Conclusions</p><p>Our findings elucidate a detrimental role of PAR-1 in vascular dysfunction and profibrotic responses upon tissue injury during AKI-to-CKD transition and provide an attractive therapeutic strategy for post-injury repair in AKI.</p>-
dc.languageeng-
dc.publisherOxford University Press-
dc.relation.ispartofNephrology Dialysis Transplantation-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleTubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition-
dc.typeArticle-
dc.identifier.doi10.1093/ndt/gfad051-
dc.identifier.volume38-
dc.identifier.issue10-
dc.identifier.spage2232-
dc.identifier.epage2247-
dc.identifier.eissn1460-2385-
dc.identifier.issnl0931-0509-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats